OncoMatch

OncoMatch/Esophageal Cancer/PD-L1 (CD274)

Esophageal CancerPD-L1 (CD274) Clinical Trials

38 recruiting trials·Updated daily from ClinicalTrials.gov

PD-L1 CPS ≥10 is the key biomarker threshold for first-line nivolumab plus chemotherapy (CheckMate 648) and pembrolizumab plus chemotherapy (KEYNOTE-590) approvals in esophageal carcinoma; both checkpoint-containing regimens are approved regardless of PD-L1 but with greater benefit at CPS ≥10. Nivolumab monotherapy is approved for PD-L1 TPS ≥1% in second-line esophageal squamous cell carcinoma. Trials investigate novel IO combinations, chemoradiation plus checkpoint therapy, and perioperative IO for resectable disease.

Match trials to my profileClinician mode →
Top recruiting

Top recruiting PD-L1 (CD274) Esophageal Cancer trials

Ranked by phase and US site count.

See all trials matched to your profile →
Phase 357 US sites

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

AstraZeneca

Phase 337 US sites

A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer

Astellas Pharma Global Development, Inc.

Phase 3

A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer

Astellas Pharma Global Development, Inc.

Phase 2/Phase 3

DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy

RemeGen Co., Ltd.

Phase 3

M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.

FutureGen Biopharmaceutical (Beijing) Co., Ltd

Phase 3

A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Shandong Boan Biotechnology Co., Ltd

Additional trials

More PD-L1 (CD274) Esophageal Cancer trials

See all in search →
Phase 2
20 international trials (no US sites)
NCT05919030A Study of Chemoradiation in Combination with Tislelizumab As First Line Treatment in Participants with Advanced Esophageal Squamous Cell CarcinomaPhase 3NCT07733830Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCCPhase 2NCT07699939Perioperative HLX10 (Serplulimab) With S-1+Oxaliplatin (SOX) in Locally Advanced and PD-L1-Positive Gastric or Esophagogastric Junction AdenocarcinomaPhase 2NCT06742411XELOX Combined With Sintilimab and HBO for Advanced or Metastatic GC/GEJCPhase 1/Phase 2NCT07311408SHR-1701 + Rivoceranib (± SHR-2554) in Advanced GC After First-Line Immunotherapy FailurePhase 2NCT06769113A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard TherapyPhase 2NCT05507411Watch and Wait for NeoAdjuvant Concurrent Radiochemotherapy Combined With Camrelizumab in Patients With Resectable ESCCPhase 2NCT06885814Efficacy and Safety of Adebrelimab Combined With Chemoradiotherapy in Patients With Unresectable Locally Advanced or Postoperative Recurrent Esophageal Squamous Cell CarcinomaPhase 2NCT07290010The Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy as the First-line Treatment for Esophageal Squamous Cell CarcinomaPhase 2NCT05182944A Study of Perioperative Camrelizumab Combined With Chemotherapy in Patients With Resectable ESCCPhase 2NCT05473156A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected MalignanciesPhase 1/Phase 2NCT06452602Induction Immunochemotherapy Followed by Concurrent Chemoradiotherapy in Patients With ESCC.Phase 2NCT06354218Serplulimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old AgePhase 2NCT06061146Tislelizumab Plus Concurrent Chemoradiation in Older With ESCCPhase 2NCT07038629Chemoradiation Plus Iparomlimab Consolidation in Older With ESCCPhase 2NCT06468280Synergistic Effects of PD-1 Antibody and Chemotherapy/Targeted Therapy Followed by Surgery-centric Local Treatment in Patients With Limited-metastatic Gastric CancerPhase 2NCT06422403A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced CancersPhase 2NCT07152678Brachytherapy With Radiotherapy and Immunotherapy: Guided HDR Trial in Esophageal Squamous Cell CarcinomaPhase 2NCT06601309Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCCPhase 2NCT07176312Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) PatientsPhase 2
Other Esophageal Cancer biomarkers

Browse other molecular targets with active Esophageal Cancer trials.

HER2 (ERBB2)FGFR2
← All Esophageal Cancer clinical trials